2 Helen Diller Comprehensive Cancer Center, UCSF, San Francisco, California, USA.
3Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA.
4Department of Neurological Surgery, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
A study conducted by the Sant Pau Research Institute (IR Sant Pau) and Hospital de Sant Pau has identified for the first time in living individuals a brain pattern related to the tau protein that changes according to the stage of Huntington’s disease. This discovery opens the door both to the use of new biomarkers for monitoring the disease and to the development of treatments for a condition for which no therapeutic options are currently available.
Using positron emission tomography—a molecular neuroimaging technique known as PET—and the second-generation radiotracer [¹⁸F]PI-2620, the researchers demonstrated that this signal can already be detected in some mutation carriers who have not yet developed clinically manifest disease and that, as the disease progresses, the signal increases and spreads according to an organized anatomical distribution.
The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, provides new insights into the biological processes that occur between the genetic alteration responsible for the disease and the onset of its motor, cognitive and neuropsychiatric manifestations.
Researchers are beginning to realize that even vastly different psychiatric disorders can share startlingly similar genetic roots.
In February last year, scientists revealed their discovery that eight different psychiatric conditions all shared a common genetic basis.
Another team then published a follow-up study in Nature in December – the largest of its kind to date.
A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital and numerous partner institutions have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.
Gliomas are usually incurable brain tumors that are difficult to remove completely through surgery. Chemotherapy and radiation therapy are also effective only to a limited extent. These tumors often share a key characteristic: In most cases, the cancer cells carry a common genetic mutation. An identical genetic error causes a specific amino acid to be substituted in the IDH1 enzyme. This results in a novel protein structure—a so-called neoepitope. What makes this special is that the neoepitope drives tumor growth and, at the same time, is recognized as foreign by the patient’s immune system, making it an ideal target for immunotherapies.
The research team from Heidelberg/Mannheim and Tübingen developed a peptide vaccine that specifically trains the immune system to recognize and fight tumor cells with this mutation. The vaccine was tested for safety and efficacy in a phase 1 clinical trial (NOA 16) involving 33 patients with newly diagnosed high-grade astrocytomas, the most common form of glioma. The patients received the vaccine in addition to standard therapy consisting of surgery, radiation therapy and chemotherapy. The work is published in the journal Nature Cancer.
What happens when the laws of the universe turn against existence itself?
In this cinematic 4K documentary, we journey through a hierarchy of cosmic catastrophes that challenge the survival of any civilization, from the localized death of planets to the absolute collapse of physical laws.
▶A Film by: Scienshell Studio.
In a universe governed by deep time and immense forces, disaster is not a matter of if, but when. From worlds frozen in perpetual schizophrenia by tidal locking to the ultimate recollapse of space-time, civilizations must either evolve to engineer the cosmos or face total eradication.
But as the scale of destruction grows, the line between technology and natural law begins to blur. For those who survive the end of the universe, reality itself becomes a blank canvas.
In this video, you’ll discover:
00:00 Introduction.
02:35 Tidally Locked Worlds and Planetary Accelerators.
05:35 Stellar Storms and Planetary Shield.
08:43 Supernovae and Star Lifting.
11:53 Supermassive Black Holes and The Space Nomads.
14:54 Interstellar Interceptors: The Predator and the Prey.
17:08 The Inflaton Field and The Big Crunch.
21:01 Higgs Field Decay: The Death of Matter and Gravity.
22:31 Beyond Physics: Civillization with godly powers.
▶ About This Video.
For decades, neuroscientists have known that specific regions in the brain’s left hemisphere are responsible for processing language. However, a new study by MIT researchers shows that language processing also occurs in many other parts of the brain.
Using functional magnetic resonance imaging (fMRI) data from more than 700 people, the researchers identified 17 additional regions of the brain that appear to play a role in language. These regions are scattered across the brain, including parts of the cerebellum, hippocampus and cerebral cortex, and they make up about 5% of the total volume of the adult brain—about the size of a large strawberry.
“Even though there are all these distant components, it’s pretty restricted in terms of volume. You don’t need that much of the brain to do language,” says Evelina Fedorenko, an MIT associate professor of brain and cognitive sciences, a member of MIT’s McGovern Institute for Brain Research, and the senior author of the study.
Age-related neurodegenerative disorders, including dementia, are a major global health concern. This article describes the first comprehensive, data-driven molecular model of the neuro-glia-vascular system to explore the complex relationships between the aging brain, energy metabolism, blood flow, and neuronal activity. Comprising 16,800 interaction pathways, the model includes all key enzymes, transporters, metabolites, and circulatory factors vital for neuronal electrical activity. We found significant alterations in metabolite concentrations and differential effects on adenosine triphosphate (ATP) supply in neurons and astrocytes and within subcellular compartments in aged brains and identified reduced sodium/potassium adenosine triphosphatase (Na+/K+-ATPase) activity as the leading cause of impaired neuronal action potentials.
On Sunday, July 5, 2026, at 1 p.m. U.S. Pacific Time, watch a compilation stream of four additional presentations from the May 2–3, 2026, sessions at the University of California, Berkeley Conference on Aging and Longevity (BerkeleyCAL), hosted by Professor Steven A. Garan, Director of Bioinformatics at the Center for Research and Education on Aging.
These presentations focus key insights in geroscience, both from its history and in regard to promising future directions and some implications for effective advocacy; they are delivered by some of the leading researchers in longevity science – Aubrey de Grey, Brendan Hughes, Felipe Sierra, and Michael West. Three of the presentations include question-and-answer sessions.
Dr. Aubrey de Grey of the Longevity Escape Velocity Foundation (LEVF) discusses the historical approaches to viewing aging and their shortcomings, as well as the damage-repair approach that he has championed and its prospects for rejuvenating the body. He also discusses implications for advocacy and which tactics could be more effective in bringing the public on board. Note: This presentation is an excerpt, captured by USTP Chairman Stolyarov on his phone camera. It is being made available due to the official recording having been lost.
Dr. Brendan Hughes from the Buck Institute discusses his thesis research on how DNA damage shapes unique, disease-relevant senescent cell states in neurons and other brain cell types. He details a methodology involving the direct differentiation of fibroblasts into neurons and oligodendrocytes to better understand aging-related cellular responses and potential therapeutic targets for Alzheimer’s disease. Dr. Hughes also highlights the importance of basic research in developing future interventions, such as senescence-targeted therapies or DNA repair modulations. The question-and-answer session includes a question from USTP Chairman Stolyarov to Dr. Hughes.
Dr. Felipe Sierra advocates for a shift in geroscience from solely targeting age-related diseases to focusing on maintaining intrinsic health and functional capacity. He proposes that molecular resilience acts as the crucial link between aging biology and long-term health, suggesting that strengthening this resilience could prevent the onset of multiple morbidities. Ultimately, he calls for more robust longitudinal studies and clinical trials that prioritize health-span metrics over the traditional, disease-centered approach to geriatric medicine.
Dr. Michael West explores the biological dichotomy between mortal somatic cells and the immortal germline to explain the fundamental mechanisms of aging and cellular regeneration. He discusses the history of stem-cell research and his work on telomeres and nuclear transfer, which demonstrated that developmental aging and cellular differentiation are reversible processes. Dr. West proposes a new approach to regenerative medicine that focuses on unlocking the body’s innate potential by targeting heterochrony genes to combat chronic degenerative diseases.